Researchers want to determine whether the investigational drug pazopanib lessens nosebleed severity in people with hereditary hemorrhagic telangiectasia (HHT).

Pazopanib is investigational for this use, which means it has not been approved by the US Food and Drug Administration for treating HHT.

Eligibility criteria are specific, and the study runs through participating HHT Centers of Excellence. Your HHT care team can tell you quickly whether it is realistic for you.

To learn more: write to research@curehht.org.